JADE101 for IgA Nephropathy Kidney Disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether JADE101, a new medicine, can help slow kidney damage in people with IgA nephropathy (a type of kidney disease caused by immune system problems). You'll take it alongside your current blood pressure medications for about 48 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Between 18 and 60 years old
- Kidney function test (eGFR) score of at least 30
- Confirmed IgA nephropathy diagnosis from a kidney biopsy
- Currently taking an ACE inhibitor or ARB blood pressure medication at a stable dose for at least 12 weeks
- Protein level in urine (UPCR) of at least 0.75 g/g
- Able to attend regular visits and follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests a new medicine called BHV-1400 for adults with IgA nephropathy, a kidney disease that can cause protein in the urine and kidney damage. The goal is to see if it's safe and effective in slowing the disease.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.